N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

Sponsor: Analog Device, Inc. • ClinicalTrials.gov ID: NCT05650541

Registry updated: 2026-08-19
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The primary purpose for this study is to support the hypothesis (pilot data) that the use of the Sensinel CPM system reduces the rate of HF-related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the primary objective, the study will compare the outcomes and costs for patients using the Sensinel CPM system against those who are not. This can either be done using institutions' averages, if available, or through a control group.

Interventions

  • CardioPumlonary Management System (Device)
    The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.

Eligibility criteria

Inclusion Criteria: Heart failure patients regardless of ejection fraction (HFpEF or HFrEF) with one or more of the following: * NYHA Class III HF * NYHA Class IV HF OR * NYHA Class II HF with one or more of the following: * Chronic Kidney Disease (eGFR\<60 within the past 6 months) * HF hospitalization (defined as HF listed as the major reason for hospitalization) within 9 months prior to screening visit and NT-proBNP \> 200 pg/ml\* for patients not in AF or \> 600 pg/ml\* for patients in AF on screening ECG+ * NT-proBNP \> 300 pg/ml\* for patients not in AF or \> 900 pg/ml\* for patients in AF on the screening visit ECG+ * Chronic obstructive pulmonary disease (COPD) Exclusion Criteria: * Under 18 years of age * Patients with severe COPD (GOLD stage III or IV) * Limited mobility preventing application of device or no caregiver to assist * Cognitive impairments that would limit the application and proper use of the device * Skin allergies or skin sensitivities to silicone-based adhesives * Pregnancy (method of assessment at the discretion of the PI) * Not willing to shave chest hair if needed to apply device * Patients on chronic IV ionotropic therapy - (Milrinone, Dobutamine, and Dopamine) * Patients with any condition that might limit the survival to less than 1 year as assessed by the investigator * No cellular coverage (Patient's Home)\*\* * Skin breakdown on the left chest or breast area

Conditions

Heart Failure

Locations

  • Desert Oasis Healthcare — Palm Springs, California, United States
  • Baptist Health South Florida — Miami, Florida, United States
  • Orlando Health — Orlando, Florida, United States
  • Baystate Medical Center — Springfield, Massachusetts, United States
  • University of Nebraska Medical Center — Omaha, Nebraska, United States
  • Cone Health — Greensboro, North Carolina, United States
  • Prisma Health — Greenville, South Carolina, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record